Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15558948 | 0.79 | TAAR1 (0.54) | TAAR1HTR2CSLC6A3KIF11MAOB | |
| SCHEMBL3746053 | 0.77 | LOXL2 (0.44) | LOXL2KCNN4TAAR1SLC6A2HTR2A | |
| SCHEMBL1463293 | 0.76 | MAPT (0.44) | LOXL2TAAR1KIF11RAB9AMAOB | |
| SCHEMBL4110242 | 0.75 | CYP3A4 (0.50) | LOXL2KCNN4TAAR1USP2RAB9A | |
| SCHEMBL1619364 | 0.75 | TAAR1 (0.60) | LOXL2KCNN4TAAR1SLC6A2HTR2A | |
| SCHEMBL5308364 | 0.75 | LOXL2 (0.42) | LOXL2KCNN4TAAR1SLC6A2HTR2A | |
| SCHEMBL3264276 | 0.74 | HTR2A (0.42) | TAAR1HTR2AHTR2CHTR2BMAOB | |
| SCHEMBL6641361 | 0.74 | ESR1 (0.46) | TAAR1SLC6A2SLC6A4SLC6A3KIF11 | |
| SCHEMBL6060758 | 0.74 | TSHR (0.48) | TAAR1HTR2AHTR2CHTR2BKIF11 | |
| SCHEMBL4976900 | 0.74 | TSHR (0.46) | TAAR1SLC6A2HTR2AHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108276542-A | A kind of method that high yield prepares fluorine-containing polyureas mono-dispersion microballoon | 济南大学 | 2018-07-13 | — | — | CN | claimed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | claimed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | claimed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | claimed |
| CN-108276542-A | A kind of method that high yield prepares fluorine-containing polyureas mono-dispersion microballoon | 济南大学 | 2018-07-13 | — | — | CN | disclosed |
| EP-2292595-A1 | Potassium channel modulators | NeuroSearch AS (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | disclosed |
| US-20060135559-A1 | Novel imidazoline compounds | MSD K.K. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-7064142-B2 | Imidazonline compounds | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-4730068-A | SPECIAL EFFECT ON BREAST CANCER | ASTA-WERKE AKTIENGESELLSCHAFT (DE) | 1988-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135559-A1 | Novel imidazoline compounds | GPR119, NPY1R, NPY2R | LOXL2 2523/4885KCNN4 1829/4885TAAR1 333/4885 |
| US-20030158418-A1 | Novel imidazonline compounds | NPY1R, NPY2R, GPR119 | LOXL2 1114/4885KCNN4 2042/4885TAAR1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.